MoonLake Immunotherapeutics Quarterly Cash Flow Statement
NASDAQ: MLTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
10.82+0.24 (+2.27%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
MoonLake Immunotherapeutics free cash flow
In the quarter ended Jun 30, 2026, MoonLake Immunotherapeutics generated -$55.6 million of operating cash flow and spent $0 on capital expenditures. That left free cash flow of -$55.6 million.
Summary generated from market data by MetaCap's automated system. Methodology
MoonLake Immunotherapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -61.80M | -69.71M | -63.02M | -70.69M | -56.05M | -40.56M | -46.40M | -36.11M | -24.76M | -13.97M | -7.89M | -11.62M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 896.00K | 845.00K | 751.00K | 745.00K | 742.00K | 378.00K | 364.00K | 351.00K | 342.00K | 328.00K | 3.29K | 3.29K |
| Stock-Based Compensation | 2.55M | 13.36M | 3.59M | 3.71M | 3.31M | 2.29M | 1.93M | 1.84M | 1.83M | 1.68M | 1.61M | 1.43M |
| Change in Working Capital | -6.34M | -6.17M | 4.27M | 8.20M | 5.07M | 3.01M | -1.72M | 5.57M | 1.66M | 1.65M | -1.57M | -955.20K |
| Operating Cash Flow | -55.56M | -66.29M | -58.79M | -44.54M | -54.53M | -38.14M | -48.47M | -25.28M | -27.89M | -14.95M | -12.34M | -9.25M |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | -35.00K | -176.00K | -132.00K | 0 | -212.00K | -284.00K | 0 |
| Investing Cash Flow | 322.00K | 98.00K | -29.91M | 88.40M | 88.25M | 56.25M | -147.33M | 58.28M | -87.74M | -28.80M | 116.87M | -174.38M |
| Share Repurchases | — | — | — | — | — | — | 0 | 0 | 0 | -50 | 0 | 0 |
| Debt Issued | 0 | 24.47M | 0 | 0 | 0 | 73.02M | 0 | 0 | 0 | 0 | — | — |
| Financing Cash Flow | 234.62M | 30.64M | 72.39M | 480.00K | 0 | 73.12M | 151.00K | 183.00K | 0 | 50.98M | 28.42M | 0 |
| Net Change in Cash | 179.41M | -36.03M | -16.22M | 44.05M | 35.12M | 91.14M | -195.23M | 32.86M | -115.65M | 7.27M | 133.00M | -183.62M |
| Free Cash Flow | -55.56M | -66.29M | -58.79M | -44.54M | -54.53M | -38.17M | -48.65M | -25.41M | -27.89M | -15.16M | -12.63M | -9.25M |
This table shows 12 quarterly periods of MoonLake Immunotherapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow MLTX's reporting calendar. What is a cash flow statement?